{
    "ticker": "EVX",
    "name": "Evox Therapeutics plc",
    "description": "Evox Therapeutics plc is a biotechnology company focused on the development of exosome-based therapies for the treatment of a range of diseases, including genetic disorders and cancer. Founded in 2016 and based in Oxford, UK, Evox leverages its proprietary exosome platform to engineer exosomes that can deliver therapeutic payloads, such as RNA and proteins, directly to target cells in a safe and effective manner. The company's innovative approach aims to overcome the limitations of traditional drug delivery methods, enhancing both the efficacy and safety of treatments. With a robust pipeline of product candidates, Evox is at the forefront of exosome research and development, collaborating with leading academic institutions and industry partners to advance its technologies. The company is committed to transforming how diseases are treated and improving patient outcomes through cutting-edge science and technology. Evox's mission is to harness the natural properties of exosomes to develop new therapies that address unmet medical needs and provide hope for patients with serious health conditions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Oxford, United Kingdom",
    "founded": "2016",
    "website": "https://www.evoxtx.com",
    "ceo": "Amit Sinha",
    "social_media": {
        "twitter": "https://twitter.com/EvoxTherapeutics",
        "linkedin": "https://www.linkedin.com/company/evox-therapeutics/"
    },
    "investor_relations": "https://www.evoxtx.com/investors",
    "key_executives": [
        {
            "name": "Amit Sinha",
            "position": "CEO"
        },
        {
            "name": "Robert K. S. Rudd",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Exosome-based RNA therapies",
                "Exosome-based protein therapies"
            ]
        }
    ],
    "seo": {
        "meta_title": "Evox Therapeutics plc | Innovative Exosome-based Therapies",
        "meta_description": "Evox Therapeutics is a leader in biotechnology, specializing in the development of exosome-based therapies for genetic disorders and cancer. Learn more about our mission and pipeline.",
        "keywords": [
            "Evox",
            "Exosome Therapies",
            "Biotechnology",
            "Genetic Disorders",
            "Cancer Treatment"
        ]
    },
    "faq": [
        {
            "question": "What is Evox Therapeutics known for?",
            "answer": "Evox Therapeutics is known for developing innovative exosome-based therapies for various diseases, including genetic disorders and cancer."
        },
        {
            "question": "Who is the CEO of Evox Therapeutics?",
            "answer": "Amit Sinha is the CEO of Evox Therapeutics plc."
        },
        {
            "question": "Where is Evox Therapeutics headquartered?",
            "answer": "Evox Therapeutics is headquartered in Oxford, United Kingdom."
        },
        {
            "question": "What are Evox's main products?",
            "answer": "Evox's main products include exosome-based RNA and protein therapies."
        },
        {
            "question": "When was Evox Therapeutics founded?",
            "answer": "Evox Therapeutics was founded in 2016."
        }
    ],
    "competitors": [
        "MRNA",
        "BMRN",
        "CRSP",
        "EDIT"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "VRTX"
    ]
}